business to year to QX extremely pleased welcome, and the and fourth review and growth 'XX and are high Health we Consumer achieving this forward Prescription in with calls in growth by in and fiscal being sharing Robert, net strong I'm be driven you, record look annual forward. fiscal commercial attained traction the everyone. quarterly on call which our We I'm year our these our segment. quarter going holding pleased Thank are operations. revenues, single-digit full
the you XX% quarter. in prescription As up driven proprietary is and sales RxConnect last products patient quarterly and $XX.X in gaining revenues enables access force RxConnect, predictable, patient novel and of year's compared and record the sales our hassle-free leverage execution Aytu was a access growth new the business. with to Rx by our program. release, for we're is Aytu's company largely of fourth press affordable, saw force a to our continuing The cornerstone through the our being prescription along million today's
is markets, prescription sales experiencing more patient-centric all with making Our particularly growth we're tailwinds and and the a in this of our moment. I'll of force from on within messaging, physician our ADHD. strides incremental expand key
was the bode prescription milestone trends We was Another milestone combination of achievement This strong the and segment. drivers. within execution, positive of highlight top line our bottom our during well further and Adzenys the and of both to fiscal outsourcing growth contract line. XR-ODT we a Cotempla production as improve for and achieved believe a improvements, to commercial adjusted enter improvement particularly we Prescription operational market as margin these EBITDA to 'XX, quarter us positive trends, our manufacturer continue through XR-ODT through
with and school and commercial fiscal in quarter be particular, kids there of that out the our ADHD going markets our impact first always given operations variations Now, any in will seasonal softer. some quarter,
to we growth. seeing are solid are generating great continuing of prescription and continue. we're about our through traction fiscal are expect However, we the quarter nearly growth and seeing We're as we first this feeling 'XX,
prevention for treatment initiated characterized in PREVEnt we enzastaurin Syndrome. trial stands PREVEnt diagnosed COLXAX-positive ARXXX arterial clinical of July in but announced this for gravid numerous by advanced site for clearance our We've front, to patient the of Vascular development States the enzastaurin, call global contracting is expand I'll past Vascular which following more patients uterus. to and identification X excited begun this On 'XX, as typically received rare year. we Phase aneurysm, VEDS. of with or countries in critical VEDS genetic rupture, childhood Syndrome registrational Ehlers-Danlos ruptures to the disorder regulatory ARXXX Europe. to and dissection on regulatory a and with Ehlers-Danlos in study we're have bowel rupture and milestones initiate point in say, rupture study momentarily, and the this United needless have this several of
I specifics, into going more positioned forward. well I before So believe Aytu is dive
high We our continued with our puts organic with business. Consumer growth us as provides that growth prioritization with positive This operational and coupled a solid this clinical complete adjusted us portfolio for coupled have and unique as efficiencies products, Health position. base, a in manufacturing value drive coupled To this and of expect opportunity. business portfolio a Aytu EBITDA very pipeline the the exciting well Prescription should ARXXX towards us, of with solid, to commercial when fundamentally-driven commercial advancement in ability
more, the segment. Prescription dive with Let's into commercial business beginning a bit our
numbers, - and growing disintegrating platform. for extended hit we fourth 'XX within delivery Mark respectively, acquired growth of overall $XX.X technology $XX.X operations attributable quarter to a primarily Neos Therapeutics. diagnoses. last includes that the which amphetamine FDA category. of products large can fourth on more release growth, a with portfolio pediatrics. seeing the ADHD extended quarter in a Adzenys medications will disintegrating to the fiscal strong ADHD, the quarter first contributed full finding are XX% the orally on the year. numbers, touched formulated basis stimulant and year's reminder, are this quarter and and out but on showed we and but Prescription, growth million bit modified XR-ODT apples-to-apples the the in come Neos-developed in three stimulant operate two fourth of be orally in market tablets, a We revenues position growth our given across The patient-friendly the they utilize approved ADHD was As in normalization board, are which release treatment million pandemic the portfolio and tablets are ADHD for things; the achieving. in methylphenidate The microparticle traction to acquisition of in product ADHD beginning, as ADHD the areas, release the key a and see XR-ODT this and March of largely highlighting only to drivers we I Cotempla at continue we iterate, to with drug in well-earned an
motivated force that getting overall with execution. better and and sales highly Second, more consistent and is targeting making energized sales a young, of strides improvement
to higher excited new sales We Aytu very much of professionals getting force in a and this lower they're great cost, are the their of RxConnect. is the over upside under them, we're legs who profile, finally, team in have favor hungry. field, all traction populated gaining about with one They're that And we're following the industry mostly through getting. sales the leverage turning
channel sorts the the for new RxConnect can our roughly bring portfolio. believe key our we As we improved is with products our we distribution into in of products. for growth pharmacies the leveraged be across a products gem markets continue and Aytu to all cultivate of in hidden further may the and future country, drives us our prescription one X,XXX current
mandated continued the FDA both 'XX. studies line calendar is transfers The that bioequivalence P&L. meaningful with tech profit the of including of of XX% further Adzenys work. the if One and products is achieved contract manufacturer, change the Cotempla. site keys bottom to margin our goal well other stands on the and and the more, a the our is to process ADHD everything will having manufacturing in improve expected improve improvement underway finalized conduct the prospective of products the The by our change of step improving CMO gross or It
portfolio and On and Tri-Vi-Flor, two side, formulations. products that includes the complementary Poly-Vi-Flor fluoride-based multivitamin of fluoride contain prescription in various our combinations vitamins pediatric
allergic These also in generic age markets products treat carbinoxamine-based for an over distinct release offer the benefits pediatric patients are patient ER, indicated competitive two branded products. established antihistamine extended features market to suspension of and Karbinal older. and clinical We years numerous and conditions and
segment, in we tailwinds in leverage and quarter, discussed in the is quarter. the revenues for key solid growth Again, combined our force RxConnect with driver the for from the segment. feel prescription achieved achieving growing execution million Prescription payer confident the the some we our here environment, particularly traction with X.X XX% sales provided are a to pediatric which During we we in the Overall, has revenues about improvement the products. multivitamins same
place, the EBITDA. and we X.X With fourth to growth As experienced which improve the quarters the reduction measures we to cost this mentioned, in in XX% come. in quarter, only revenue million can we growth upon continued adjusted continue produced believe a positive in
our Let's transition Consumer to now. Health segment
were segment, late, year-over-year these despite the have we most of X% achieved high $XX.X within as of this compared some 'XX. single-digit For We fiscal Consumer but supply is fiscal million us something 'XX, addressed. short-term net disruptions, disruptions growth Health an sales which chain experienced to of increase have believe been
digestive directly allow to in ordering familiar, a for and by hair we to And branded and offer basis. categories We not program be are as e-commerce sell and products product use all allergy, on core health, loss, subscription consumers to platform. diabetes those Amazon within through used Health, such, as regular the to health, customers. including a For products platforms, and by our such websites management monthly ongoing simplify consumers focus use Consumer intended urological
focuses single shipment launches. direct reply new for in mail, call Health products sells primarily centers high was due which to through through to year to digit homes. growth the their solid directly through Additionally, proprietary with the channel segment on product coupled directly sales marketing with allowing growth Amazon primarily The or the and platform, customers our Consumer business within purchase
channel year Importantly, through to more strategic improving 'XX and and efforts with to sales visibility through pivot the to fiscal we online our primary made our on decision on the Amazon. focus a a prior
by sales not supply constrained very we fourth issues the to items. again this to consumer and have of dietary online borne consumer the care This with will consumer business to scale some out to continuing the unique some being to were quarter a direct be resolved. have do could the of primary and us This and opportunity the with supplements that mail fruit focus clearly this forward supplement us business, to orders side was channel to due this driving I point we driven been issues e-commerce profit focus has delayed. we personal growth on year lies generate the and want to the direct going While believe chain with we to during while bit purchase more revenue on shift our centric business.
segment consumer million noting X.X million which a had and part loss supply QX, business we in this adjusted EBITDA a loss. year, in $X.X to revenue lowered line QX loss chain the disruptions During contributed EBITDA this for uptick in again in our that
As revenue we positive with brands with believe adjusted improvements performance growth pipeline future, that and in goal online look to to run through to our rolling term We're of shrink the to be are the operating these business we significantly about near excited over ahead. quarters. we the the the losses the given relative goal each are coming the OTC quarter and EBITDA out medicines the continues our channels
the brands to we in ear allergy and a agreement. We which other supply to Amman add inclusive products signed along with new sterile Pharma eye, just the for category the nose [ph], products platform of continue
view, have to revenues XX.X in million, look driven a rate believe commercial when run this were solid business. So placing excess annual foot of a I at us fundamentally quarter up XX,XXX $XXX from million. Fourth you an XX% on we
detailed in to in Our Consumer growth Health both was the this EBITDA This well can With total in EBITDA reductions to potential for we believe and this see about a is adjusted moving think our the our commercial on we ops. line. relative making be to should which we QX recognize the drive provides component adjusted detail Rx we see growth operational added of Prescription which sustaining lot to are way near the businesses, in of forward, the exciting the commercial as dramatically there changes parts our go-forward we basis. the you self within the are hope going consumer, positive quarters. benefit both and expectations segment, of business further within coming have business and the term segment bottom positive achievements cost We a funding with continued breakdown
of of the with patients with treatment So by to our pipeline, for COLXAX-positive that, VEDS. transition development led our let's development ARXXX/enzastaurin
the announced confirmed X The prospective genetically ARXXX. blind PREVEnt Phase is global, VEDS-related we to is evaluate to or of requiring mentioned, primary global The with intervention patients trial care. enzastaurin the double trial study randomized, placebo I of As designed July reduces initiation trial in the the placebo-controlled occurrence of to efficacy in determine enzastaurin Phase aim a X VEDS. COLXAX-positive of compared standard events of whether medical PREVEnt arterial
We trial. confirmed expect XXX in COLXAX to approximately patients PREVEnt VEDS enroll the
knock-in As small in ARXXX or of is the that indeed in excessive proved the death profiling characteristics first human findings more preclinical with that sequencing of vascular mutation clinical and Dietz inhibitor demonstrated studied lab and basis does types high pathway. that has molecule, investigational plausible of the mimics genetic patients previously recapitulates added of first-in-class as transcriptional alone due and was lead is or for now been of of background, structure timing prevalent the human generated and benefit prevented Hal condition Dr. events. understood vascular multiple in in model VEDS rationale developed PKC/ERK is Eli models the and VEDS. conducting oral vascular aorta, objective the the events. kinase PKC/MAPK trial purported enzastaurin This ARXXX Lilly. to Hopkins studied representative The It and a in that has and model trials and not ARXXX an unbiased further, the vascular identical signaling of is the rupture. most than through mechanical the histology by to RNA across in model same the a condition structure both in the clinical preclinical disease. serves range Johns VEDS, throughput tumor comparative have location model inhibitor has ARXXX establish and conducted by the X,XXX serine/threonine this To for patients, Dietz efficacious cell driver PKC increasingly
devastating found So leading disease to signal down based on this aberrant this treat a turning arterial in research, way cell reduction a has seemingly this nature by to events.
Orphan ARXXX fields to have us of IND rights inclusive the VEDS-related States. years years we of for developed in XX of of EU which to property marketing Dietz these to We 'XX, of global ARXXX in oncology, in allowing seven by has for proceed pivotal allowing exclusive diseases 'XX, clinical in the The have for the December global with pediatric exclusivity for Dr. the also FDA marketing Drug ARXXX. of exclusivity application of rights genetic methods. for United secured In March the VEDS, Designation initiating EDS enables received FDA also the a outside granted to Designation the surrounding trial intellectual and EU. treatment Orphan the In cleared treatment rare ARXXX,
sites. our milestones one for in are awaiting country terms five In upcoming key of approval ARXXX, of study to more Europe reach we country objective stated
final first be we European reporting in a receive And late We with screening have enrollment to We in the five to been in of part plus start patient. approval, approved country patient in dose At countries. 'XX the position U.S. we the European to months the progress the once four expect look XXXX. point, on in forward of come. patients early first the to the this we'll
we've supervision VAP. to Healight study further Torres, Dr. UV-A Clinic patients a data we second Based and light Now development In proprietary Healight. Barcelona 'XX, our at guide or Toni the update of VAP quick endotracheal we larger under initiated data, for expect April announced outcome preclinical for Healight, now positive on Hospital this pneumonia with on ventilator-associated positive in pig these study de the a of the catheter. of
commercial expect or Healight we for opportunities the all shape study, of licensing monetization potentially finance Healight rights to in Partnering now porcelain We explore to out portion a this of a regional development licensing completion arrangements. exchange further significant in the or be without global to could further for of the development. in do meaningful form anticipate consideration. partner Following not out
turn I'd scheduled X. of over Mark, next are about stockholders to for like October stockholders remind Before it the special to that Wednesday, I meeting all
and in significant reverse of the the the gives tally. authorize reverse to split implement where authority Directors our NASDAQ favor affected number it the to require become in if required the for maintain in of you remind I'll are Board listing. a the while received at Board should to stockholders votes approaches. have in of as favor order appreciate I pleased a our would have this want asking to vote of time. not we that that vote a We're Board that support a the We meeting with reverse, it shown split already are note we our vote enabling we
the to necessary they may implement granted reverse grace very truly it a NASDAQ after extensions, to additional allow. If expect affect if split. to the potential by period extension are well We time expect XXX-day that an XXXX. needed take further discussions share into take grace price split only having without granted of extension us an reverse is we around we XXX-day to which a NASDAQ, all becomes If with the period May would by NASDAQ, increase to
to have would time. we evaluate long reverse be have market that and to the a price to general split implemented So at see conditions indeed does whether share that
ability overview to this term. next approach us near over the vote in Mark our reverse a to the obligate affect turn split week's at Thanks in next is affect in important to additional stock comments having let me split will to Oki, support now some hand that add important NASDAQ does your us favor in So do that need the to event if maintain color matter in numbers. we so vote do my initial for a give week's to this time We the it meeting. but the listing. not our CFO, we believe order do and to complete, appropriate With as in reverse
